IMBiologics Passes KOSDAQ Technical Evaluation with 'A, A' Ratings

Published: August 4, 2025, 07:30 KST | Updated: August 4, 2025, 07:30 KST
By Sungmin Kim, BioSpectator

Company Initiates Official KOSDAQ Listing Process, Plans to Submit Preliminary Review Application

IMBiologics announced on August 4 that it has passed the technical evaluation required for a technology-based special listing on the KOSDAQ market.

The company received “A, A” ratings from two professional evaluation agencies designated by the Korea Exchange, demonstrating recognition for both its technological capabilities and business potential. IMBiologics plans to submit its preliminary listing application as soon as possible, with the goal of filing a securities registration statement by the end of this year or in the first quarter of next year.

Founded in August 2020, IMBiologics is a biotech company focused on developing innovative new drugs based on immuno-modulatory biologics.

Its lead program, “IMB-101,” is a bispecific antibody targeting OX40LxTNF for the treatment of autoimmune diseases. In June last year, the company signed a license-out (L/O) agreement with U.S.-based Navigator Medicines, followed by another deal with China’s Huadong Medicine in August. The respective deals were valued at $944.75 million and $307.5 million. IMBiologics confirmed the safety and tolerability of IMB-101 in a Phase 1a clinical trial, and its partners are currently conducting Phase 1b trials.

In addition, the company is expanding its research and development portfolio through in-house programs using its proprietary multivalent antibody backbone platform, “ePENDY” (enhanced/engineered PENtamer boDY), to develop treatments for autoimmune diseases, immuno-oncology, and ophthalmologic conditions.

Ha Kyung-sik, CEO of IMBiologics, stated, “This technical evaluation officially acknowledges the completeness and competitiveness of our new drug development technologies, as well as our commercialization capabilities. We will diligently carry out the remaining steps toward our KOSDAQ listing and strive to achieve meaningful business outcomes each year, becoming a trusted company in the market that prioritizes its promises to shareholders.”

For press inquiries: sungmin.kim@bios.co.kr
© BioSpectator. Unauthorized reproduction, redistribution, or use for AI training is prohibited.